-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Polypeptide drug is a special drug between small molecule and protein drugs.
Compared with general small molecule drugs, it has the advantages of high activity and safety, strong specificity, good certainty, and good druggability.
Therefore, It has a wide range of clinical applications and broad prospects.
At present, whether in the domestic or international markets, the peptide drug industry has shown a good momentum of rapid development
.
Data shows that the sales of peptide drugs in China will reach 35.
78 billion yuan in 2020, and it is expected to reach 38.
71 billion yuan in 2021
.
With the introduction of a series of policies to encourage the development of innovative drugs and the consistency evaluation of generic drugs in China, it is expected that the domestic peptide drug market will further expand in the future
.
At present, there are more than 40 peptide drugs on the market in China, which mainly involve seven major fields, including immunity, digestive tract, anti-tumor, orthopedics, obstetrics, diabetes and cardiovascular
.
The industry pointed out that rare diseases, tumors and diabetes will be the "troika" that will drive the growth of the peptide drug market
.
Take the diabetes field as an example.
China is a big country with diabetes, with as many as 100 million patients.
This data means that about 1 out of 10 Chinese people is a diabetic, and in recent years, with the pace of domestic life accelerating , Habits have changed, and the prevalence of diabetes in China is still increasing
.
"Healthy China 2019-2030" pointed out that by 2022 and 2030, the diabetes awareness rate of residents aged 18 and above will reach 50% and above and 60% and above respectively; the standardized management rate of diabetes patients will reach 60% and above and 70% respectively And above; diabetes treatment rate, diabetes control rate, and diabetes complication screening rate continue to increase
.
With the increasing number of domestic diabetes patients, the expansion of demand for treatment, and the release of policy plans, the market for diabetes drugs will continue to grow
.
Among them, liraglutide is an important target for diabetes treatment.
According to data from Minai.
com, the sales scale of liraglutide in my country has shown a steady upward trend in recent years, and the market has reached 1.
34 billion yuan in 2020.
.
And from the point of view of sales terminals, since liraglutide entered the retail channel in 2015, the sales scale has continued to rise, from 61 million yuan in that year to 110 million yuan in 2020.
It is expected that under the policy trend of prescription outflow, retail sales It will also be expected to rise
.
For another example, in the field of oncology, conjugated drugs have been a hot field of development in recent years
.
Among them, the development of antibody-conjugated drugs (ADC) drugs is in full swing.
There are more than 40 domestic companies engaged in this field, including Rongchang Biological, Toyo Pharmaceutical, Lepu Biological, Connoa, Jiahe Biological, Biotech, etc.
The whole group is thriving
.
Data predicts that the domestic ADC market will reach 7.
4 billion and 29.
2 billion in 2024 and 2030, respectively, with a compound annual growth rate of 25.
8% from 2024 to 2030
.
It is worth mentioning that the ADC track has become more and more congested, and the research and development pipelines have gathered together, like a red sea
.
Choosing other potential conjugate drugs may help pharmaceutical companies to achieve better "curve overtaking"
.
It is understood that the clinical application of peptide-conjugated drugs (PDC) in cancer is constantly being explored
.
Compared with ADC drugs, these drugs have the advantages of small molecular weight, strong tumor penetration, low immunogenicity, large-scale synthesis by solid-phase synthesis, low production costs, and relatively good pharmacokinetics.
It is expected to become the next generation of targeted anti-tumor drugs
.
At present, only two PDC drugs have been approved for marketing, and there are not many pipelines under research.
They are still in their infancy in China.
At present, there are at least four domestic pharmaceutical companies in the development of PDC-related products
.
The industry believes that in the future, as more solid and potential pharmaceutical companies deploy in this field, it is expected to further drive the market growth of the peptide drug industry
.
Compared with general small molecule drugs, it has the advantages of high activity and safety, strong specificity, good certainty, and good druggability.
Therefore, It has a wide range of clinical applications and broad prospects.
At present, whether in the domestic or international markets, the peptide drug industry has shown a good momentum of rapid development
.
Data shows that the sales of peptide drugs in China will reach 35.
78 billion yuan in 2020, and it is expected to reach 38.
71 billion yuan in 2021
.
With the introduction of a series of policies to encourage the development of innovative drugs and the consistency evaluation of generic drugs in China, it is expected that the domestic peptide drug market will further expand in the future
.
At present, there are more than 40 peptide drugs on the market in China, which mainly involve seven major fields, including immunity, digestive tract, anti-tumor, orthopedics, obstetrics, diabetes and cardiovascular
.
The industry pointed out that rare diseases, tumors and diabetes will be the "troika" that will drive the growth of the peptide drug market
.
Take the diabetes field as an example.
China is a big country with diabetes, with as many as 100 million patients.
This data means that about 1 out of 10 Chinese people is a diabetic, and in recent years, with the pace of domestic life accelerating , Habits have changed, and the prevalence of diabetes in China is still increasing
.
"Healthy China 2019-2030" pointed out that by 2022 and 2030, the diabetes awareness rate of residents aged 18 and above will reach 50% and above and 60% and above respectively; the standardized management rate of diabetes patients will reach 60% and above and 70% respectively And above; diabetes treatment rate, diabetes control rate, and diabetes complication screening rate continue to increase
.
With the increasing number of domestic diabetes patients, the expansion of demand for treatment, and the release of policy plans, the market for diabetes drugs will continue to grow
.
Among them, liraglutide is an important target for diabetes treatment.
According to data from Minai.
com, the sales scale of liraglutide in my country has shown a steady upward trend in recent years, and the market has reached 1.
34 billion yuan in 2020.
.
And from the point of view of sales terminals, since liraglutide entered the retail channel in 2015, the sales scale has continued to rise, from 61 million yuan in that year to 110 million yuan in 2020.
It is expected that under the policy trend of prescription outflow, retail sales It will also be expected to rise
.
For another example, in the field of oncology, conjugated drugs have been a hot field of development in recent years
.
Among them, the development of antibody-conjugated drugs (ADC) drugs is in full swing.
There are more than 40 domestic companies engaged in this field, including Rongchang Biological, Toyo Pharmaceutical, Lepu Biological, Connoa, Jiahe Biological, Biotech, etc.
The whole group is thriving
.
Data predicts that the domestic ADC market will reach 7.
4 billion and 29.
2 billion in 2024 and 2030, respectively, with a compound annual growth rate of 25.
8% from 2024 to 2030
.
It is worth mentioning that the ADC track has become more and more congested, and the research and development pipelines have gathered together, like a red sea
.
Choosing other potential conjugate drugs may help pharmaceutical companies to achieve better "curve overtaking"
.
It is understood that the clinical application of peptide-conjugated drugs (PDC) in cancer is constantly being explored
.
Compared with ADC drugs, these drugs have the advantages of small molecular weight, strong tumor penetration, low immunogenicity, large-scale synthesis by solid-phase synthesis, low production costs, and relatively good pharmacokinetics.
It is expected to become the next generation of targeted anti-tumor drugs
.
At present, only two PDC drugs have been approved for marketing, and there are not many pipelines under research.
They are still in their infancy in China.
At present, there are at least four domestic pharmaceutical companies in the development of PDC-related products
.
The industry believes that in the future, as more solid and potential pharmaceutical companies deploy in this field, it is expected to further drive the market growth of the peptide drug industry
.
